Condensed Consolidated Statements of Operations and Comprehensive Income - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Revenues:
Total revenues	$ 79,943	$ 68,730
Cost and expenses:
Cost of revenues	2,239	1,043
Research and development	28,027	32,198
Selling, general and administrative	36,450	49,095
Restructuring expenses	0	3,328
Total cost and expenses	66,716	85,664
Income (loss) from operations	13,227	(16,934)
Other (expense) income:
Interest expense	(7,220)	(9,592)
Interest and investment income	777	736
(Loss) gain on derivatives	(3,466)	3,944
Other income	27
Other expense, net	(9,882)	(4,912)
Net income (loss) from continuing operations	3,345	(21,846)
Net loss from discontinued operations		(37,438)
Net income (loss) and comprehensive income	$ 3,345	$ (59,284)
Net income per share from continuing operations - basic and diluted (in dollars per share)	$ 0.02	$ (0.14)
Net loss per share from discontinued operations - basic and diluted (in dollars per share)		(0.24)
Net income (loss) per share - basic and diluted (in dollars per share)	$ 0.02	$ (0.38)
Weighted average shares used in computing net income (loss) per share - basic	158,374	154,956
Weighted average shares used in computing net income (loss) per share - diluted	159,970	154,956
Collaborative arrangements revenue
Revenues:
Total revenues	$ 74,445	$ 66,152
Sale of active pharmaceutical ingredient
Revenues:
Total revenues	$ 5,498	$ 2,578